Dataset Information

The validity and reliability of the "My Jump App" for measuring jump height of the elderly.

ABSTRACT:

Background

The ability to jump has been related to muscle strength and power, speed and amplitude of the lower limbs movements, and specifically for the elderly, the vertical jump has been shown to be a good predictor of functional capacity and risk of falling. The use of a mobile application (App) which can measure the vertical jump (i.e., iPhone App My Jump) has recently emerged as a simple, cheap and very practical tool for evaluation of jump ability. However, the validity of this tool for the elderly population has not been tested yet. The elderly usually perform very low jumps and therefore the signal-to-noise ratio may compromise the validity and reliability of this method. Thus, the aim of the current study was to verify the validity and reliability of the iPhone App "My Jump" for the evaluation of countermovement jump (CMJ) height within an elderly population.

Methods

After familiarization, 41 participants performed three CMJs assessed via a contact mat and the My Jump App. The intraclass correlation coefficient (ICC) was used to verify the relative reliability, while the coefficient of variation (CV%) and the typical error of measurement (TEM) were used to verify the absolute reliability. Pearson's correlation coefficient was used to verify the strength of the relationship between methods (i.e., concurrent validity), a Bland-Altman plot to show their agreement, and the Student's t-test to identify systematic bias between them. For reliability analyses, all jumps were considered (i.e., 123). All jumps (i.e., 123), the average height of each attempt (i.e., 41), and the highest jump, were considered for validity analyses.

Results

The CMJ height of the highest jump was 10.78 ± 5.23 cm with contact mat, and 10.87 ± 5.32 with My Jump App, with an identified systematic bias of 0.096 cm (P = 0.007). There was a nearly perfect correlation between methods (r = 0.999; P = 0.000, in all cases) with a very good agreement observed (0.3255 to -0.5177 cm, 0.2797 to -0.5594 cm, and 0.3466 to -0.6264 cm, for highest jump height, average jump height, and all jump heights, respectively). The ICC of the My Jump App was 0.948, the TEM was 1.150 cm, and the CV was 10.10%.

Conclusion

Our results suggest that the My Jump App is a valid and reliable tool compared to the contact mat for evaluating vertical jump performance in the elderly. Therefore, it allows a simple and practical assessment of lower limbs' power in this population. For the elderly, as well as for other populations with low jumping heights, the highest jump height and the average jump height could be used indistinctly.

SUBMITTER: Cruvinel-Cabral RM

PROVIDER: S-EPMC6193468 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

The validity and reliability of the "<i>My Jump App</i>" for measuring jump height of the elderly.

Cruvinel-Cabral Rejane Maria RM Oliveira-Silva Iransé I Medeiros André Ricarte AR Claudino João Gustavo JG Jiménez-Reyes Pedro P Boullosa Daniel A DA

PeerJ 20181015

<h4>Background</h4>The ability to jump has been related to muscle strength and power, speed and amplitude of the lower limbs movements, and specifically for the elderly, the vertical jump has been shown to be a good predictor of functional capacity and risk of falling. The use of a mobile application (<i>App</i>) which can measure the vertical jump (i.e., iPhone <i>App My Jump</i>) has recently emerged as a simple, cheap and very practical tool for evaluation of jump ability. However, the validi ...[more]

PMID: 30356977

Similar Datasets

Project description:BackgroundThere is strong evidence suggesting that higher levels of cardiorespiratory fitness (CRF) are associated with a healthier metabolic profile, and that CRF can serve as a powerful predictor of morbidity and mortality. In this context, a smartphone app based on the 2-km walk test (UKK test) would provide the possibility to assess CRF remotely in individuals geographically distributed around a country or continent, and even between continents, with minimal equipment and low costs.ObjectiveThe overall aim of this study was to evaluate the validity and reliability of 2kmFIT-App developed for Android and iOS mobile operating systems to estimate maximum oxygen consumption (VO2max) as an indicator of CRF. The specific aims of the study were to determine the validity of 2kmFIT-App to track distance and calculate heart rate (HR).MethodsTwenty participants were included for field-testing validation and reliability analysis. The participants completed the UKK test twice using 2kmFIT-App. Distance and HR were measured with the app as well as with accurate methods, and VO2max was estimated using the UKK test equation.ResultsThe validity results showed the following mean differences (app minus criterion): distance (-70.40, SD 51.47 meters), time (-0.59, SD 0.45 minutes), HR (-16.75, SD 9.96 beats/minute), and VO2max (3.59, SD 2.01 ml/kg/min). There was moderate validity found for HR (intraclass correlation coefficient [ICC] 0.731, 95% CI -0.211 to 0.942) and good validity found for VO2max (ICC 0.878, 95% CI -0.125 to 0.972). The reliability results showed the following mean differences (retest minus test): app distance (25.99, SD 43.21 meters), app time (-0.15, SD 0.94 seconds), pace (-0.18, SD 0.33 min/km), app HR (-4.5, 13.44 beats/minute), and app VO2max (0.92, SD 3.04 ml/kg/min). There was good reliability for app HR (ICC 0.897, 95% CI 0.742-0.959) and excellent validity for app VO2max (ICC 0.932, 95% CI 0.830-0.973). All of these findings were observed when using the app with an Android operating system, whereas validity was poor when the app was used with iOS.ConclusionsThis study shows that 2kmFIT-App is a new, scientifically valid and reliable tool able to objectively and remotely estimate CRF, HR, and distance with an Android but not iOS mobile operating system. However, certain limitations such as the time required by 2kmFIT-App to calculate HR or the temperature environment should be considered when using the app.

Project description:Background:The vertical jump is used to estimate sports performance capabilities and physical fitness in children, elderly, non-athletic and injured individuals. Different jump techniques and measurement tools are available to assess vertical jump height and peak power; however, their use is limited by access to laboratory settings, excessive cost and/or time constraints thus making these tools oftentimes unsuitable for field assessment. A popular field test uses the Vertec and the Sargent vertical jump with countermovement; however, new low cost, easy to use tools are becoming available, including the My Jump iOS mobile application (app). The purpose of this study was to assess the reliability of the My Jump relative to values obtained by the Vertec for the Sargent stand and reach vertical jump (VJ) test. Methods:One hundred and thirty-five healthy participants aged 18-39 years (94 males, 41 females) completed three maximal Sargent VJ with countermovement that were simultaneously measured using the Vertec and the My Jump. Jump heights were quantified for each jump and peak power was calculated using the Sayers equation. Four separate ICC estimates and their 95% confidence intervals were used to assess reliability. Two analyses (with jump height and calculated peak power as the dependent variables, respectively) were based on a single rater, consistency, two-way mixed-effects model, while two others (with jump height and calculated peak power as the dependent variables, respectively) were based on a single rater, absolute agreement, two-way mixed-effects model. Results:Moderate to excellent reliability relative to the degree of consistency between the Vertec and My Jump values was found for jump height (ICC = 0.813; 95% CI [0.747-0.863]) and calculated peak power (ICC = 0.926; 95% CI [0.897-0.947]). However, poor to good reliability relative to absolute agreement for VJ height (ICC = 0.665; 95% CI [0.050-0.859]) and poor to excellent reliability relative to absolute agreement for peak power (ICC = 0.851; 95% CI [0.272-0.946]) between the Vertec and My Jump values were found; Vertec VJ height, and thus, Vertec calculated peak power values, were significantly higher than those calculated from My Jump values (p < 0.0001). Discussion:The My Jump app may provide a reliable measure of vertical jump height and calculated peak power in multiple field and laboratory settings without the need of costly equipment such as force plates or Vertec. The reliability relative to degree of consistency between the Vertec and My Jump app was moderate to excellent. However, the reliability relative to absolute agreement between Vertec and My Jump values contained significant variation (based on CI values), thus, it is recommended that either the My Jump or the Vertec be used to assess VJ height in repeated measures within subjects' designs; these measurement tools should not be considered interchangeable within subjects or in group measurement designs.

Project description:Background:With the rapid increase in ageing population, China is confronted with the daunting challenge of a growing number of patients with neurocognitive disorders (NCDs). This trend makes the maintenance of self-health and early intervention essential, highlighting the need for a tool that assesses self-efficacy of older adults in maintaining brain health or cognitive function. Aim:This study aimed to design the Brain Health Self-Efficacy Scale (BHSES) to measure elderly individuals' attitudes to NCDs, motivations and future plans for controlling risks. The psychometric properties of BHSES have been validated. Methods:Based on the current literature and relevant models, a 19-item scale was created during the first stage. A total of 660 older adults in the Yinhang community of Shanghai were included. The statistical approaches of item analysis, exploratory factor analysis (EFA), confirmatory factor analysis (CFA), criterion-related validity and reliability test were used to evaluate the quality of BHSES. In addition, the Geriatric Depression Scale (GDS) and the Self-Rating Anxiety Scale (SAS) were used as criteria to test the criterion-related validity. Results:To test item differentiation, the study adopted item analysis and excluded item 8. Selecting a random half of the sample for EFA, the BHSES was refined to 16 items, which were categorised into the following three dimensions: 'memory belief efficacy', 'self-care efficacy' and 'future planning efficacy'. These were highly consistent with the hypothesis model. Its cumulative variance contribution rate reached 61.14%, with factor loads of all items above 0.5. The three-factor model was confirmed by the remaining data through CFA. All fit indices reached the acceptable level (?2=3.045, Goodness of Fit Index=0.898, adjusted Goodness of Fit Index=0.863, Comparative Fit Index=0.916, Incremental Fit Index=0.917, Tucker-Lewis Index=0.900, root mean square error of approximation=0.079 and root mean residual=0.068). The GDS and SAS scores revealed significant correlations with the BHSES score, indicating a high criterion-related validity. The overall Cronbach's ? coefficient was 0.793, with the ? coefficients' distribution of subdimensions ranging from 0.748 to 0.883. Conclusions:The 16-item, self-compiled BHSES is a reliable and valid measurement. It could help identify older adults with potential risks for developing NCDs or with high suspicion of cognitive impairment onset in recent periods and also offer insight into tracking brain health self-efficacy in association with cognition status.

Project description:BACKGROUND:A lifesaving treatment for myocardial infarction is the placement of a stent in a closed or obstructed coronary artery. The largest modifiable risk factor after receiving a stent is medication adherence to Dual AntiPlatelet Therapy, a combination of P2Y12 inhibitors and aspirin. OBJECTIVE:This study aimed to determine the acceptability of a protocol and an intervention using the My Interventional Drug-Eluting Stent Educational App (MyIDEA) and to evaluate medication adherence using the proportion of days covered (PDC) and platelet activation tests in a multisite randomized controlled trial. METHODS:Potential participants who received a post percutaneous coronary intervention (PCI) procedure with a drug-eluting stent were approached. All patients older than 50 years and who spoke English were recruited. Participants were recruited, baseline demographics were collected, and the Hospital Anxiety and Depression Scale (HADS), Rapid Estimate of Adult Literacy in Medicine-Short Form, Burden-Benefit questionnaire, 36-Item Short Form Health Survey, and PCI knowledge questionnaire were administered. Block randomization was used to randomize participants to either usual care or MyIDEA supplementation. MyIDEA is a personalized educational intervention based on the Kolb experiential learning theory using patient narratives for education. During the visits, participants' blood was collected to measure platelet suppression from medication. During the second and third encounters, the Morisky medication adherence score and cardiology outcomes were measured. The study was conducted at the University of Illinois Hospital and John H Stroger Jr Cook County Hospital with appropriate ethical approvals. Platelet suppression was measured through aspirin reactive units and P2Y12 reactive units. Medication adherence was measured using the PDC. The analysis team was blinded to the participants' group membership. The primary outcome was a feasibility analysis of recruitment and retention. RESULTS:The mean age of participants was 60.4 years (SD 7.1); the majority of patients were black and non-Hispanic. The majority of patients' reading levels were seventh grade or above, and they were not very familiar with other electronic devices for information and communication. The number of control subjects was 21, and the number of participants in the interventional arm was 24. The interventional group was able to use MyIDEA in both the hospital and outpatient setting. However, there was no significant difference in platelet suppression or medication adherence between groups. There were also differences between the groups in terms of depression and anxiety, initially, as measured by HADS. No documented adverse event associated with the intervention was found. CONCLUSIONS:Elderly patients are willing to use tablet devices to be educated about health conditions. Additional studies are required to measure the effectiveness and determine the most suitable timing and location for patient education. TRIAL REGISTRATION:ClinicalTrials.gov NCT04439864; https://clinicaltrials.gov/ct2/show/NCT04439864.